Baird initiated coverage of Crinetics Pharmaceuticals with an Outperform rating and $48 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on CRNX:
- Crinetics initiated with an Outperform at LifeSci Capital
- Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Crinetics price target lowered to $41 from $50 at JMP Securities
- Crinetics reports Q4 EPS (84c), consensus (82c)
- Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update